Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 2/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.50 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27414055 | 0.98 | TTR (0.67) | TTRAKR1C3RXRASRD5A2LPAR1 | |
| SCHEMBL13138860 | 0.88 | TTR (0.54) | TTRRXRASRD5A2LPAR1LPAR5 | |
| SCHEMBL28114618 | 0.87 | CA12 (0.57) | TTRRXRACA12CA1CA2 | |
| SCHEMBL10148365 | 0.86 | TTR (0.69) | TTRAKR1C3RXRASRD5A2LPAR1 | |
| SCHEMBL60267 | 0.85 | TTR (0.51) | TTRAKR1C3RXRASRD5A2LPAR1 | |
| SCHEMBL21363204 | 0.85 | NOTUM (0.57) | TTRNR1H4BRD4CYP1A2CYP2C9 | |
| SCHEMBL22169926 | 0.85 | TTR (0.51) | TTRAKR1C3RXRACA12CA1 | |
| SCHEMBL11462504 | 0.84 | TTR (0.81) | TTRAKR1C3SRD5A2NR1H4POLB | |
| SCHEMBL3765692 | 0.81 | TTR (1.00) | TTRAKR1C3SRD5A2POLBCASP6 | |
| SCHEMBL7148225 | 0.81 | TTR (0.88) | TTRAKR1C3SRD5A2LPAR1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897868-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2024-02-13 | — | — | US | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-01-06 | — | — | US | disclosed |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-01-06 | — | — | US | disclosed |
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2021-08-17 | — | — | US | disclosed |
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2021-08-17 | — | — | US | disclosed |
| US-20210009621-A1 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-01-14 | — | — | US | disclosed |
| US-20210009621-A1 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-01-14 | — | — | US | disclosed |
| CN-105873965-B | Random copolymer in laundry processes as detergent | 巴斯夫欧洲公司 | 2018-04-13 | — | — | CN | disclosed |
| CN-105873965-A | Random copolymers as soil release agents in laundry processes | 巴斯夫欧洲公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-105452432-A | Composition | CHEMSENTI LTD | 2016-03-30 | — | — | CN | disclosed |
| CN-103328455-B | Bleaching catalyst | BASF SE (DE) | 2016-02-24 | — | — | CN | disclosed |
| CN-105164241-A | Concentrated detergent compositions for improved starch removal in dishwashing applications | ECOLAB USA INC | 2015-12-16 | — | — | CN | disclosed |
| CN-101874079-B | Detergent composition | THE PROCTER & GAMBLE CO. (US) | 2015-11-25 | — | — | CN | disclosed |
| US-20140030741-A1 | In Vitro Method for Determining Presence of Type II Pyrethroids | GIVAUDAN S.A. (CH) | 2014-01-30 | — | — | US | disclosed |
| EP-0906402-A1 | BLEACH ACTIVATION | UNILEVER N.V. (NL) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997048787-A1 | BLEACH ACTIVATION | UNILEVER N.V. (NL) | 1997-12-24 | — | — | WO | disclosed |
| WO-1994009104-A1 | DETERGENT COMPOSITION | UNILEVER PLC (GB) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091466-B2 | Heterocyclic inhibitors of PCSK9 | PCSK9, PCSK7, PCSK6 | TTR 842/4885AKR1C3 553/4885RXRA 1184/4885 |
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK6, PCSK7 | TTR 890/4885AKR1C3 681/4885RXRA 1164/4885 |
| US-20210009621-A1 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE | AAAS, PROC, AADAC | TTR 2614/4885AKR1C3 2324/4885RXRA 2013/4885 |
| US-11897868-B2 | Heterocyclic inhibitors of PCSK9 | PCSK9, PCSK6, PCSK7 | TTR 890/4885AKR1C3 681/4885RXRA 1164/4885 |
| US-11713335-B2 | Aminocoumarin compounds and methods of their use | AAAS, PROC, AADAC | TTR 2614/4885AKR1C3 2324/4885RXRA 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.